Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

BJU International

Volumn 108, Issue 2, 2011, Pages 187-195

  Hinotsu, Shiro ^a   Akaza, Hideyuki ^b   Naito, Seiji ^c   Ozono, Seiichiro ^d   Sumiyoshi, Yoshiteru ^e   Noguchi, Sumio ^f   Yamaguchi, Akito ^g   Nagamori, Satoshi ^h   Terai, Akito ⁱ   Nasu, Yasutomo ^j   Kume, Haruki ^k   Tomita, Yoshihiko ^l   Tanaka, Yoshinori ^m   Samma, Shoji ⁿ   Uemura, Hirotsugu ^o   Koga, Hirofumi ^g   Tsushima, Tomoyasu ^p  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f YOKOSUKA KYOSAI HOSPITAL   (Japan)

^g HARASANSHIN HOSPITAL   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ KURASHIKI CENTRAL HOSPITAL   (Japan)

^j OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^k UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^l YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^m MUSASHINO RED CROSS HOSPITAL   (Japan)

ⁿ NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^o KINDAI UNIVERSITY HOSPITAL   (Japan)

^p National Hospital Organization   (Japan)

more..

Author keywords

bacillus Calmette Gu rin; intravesical therapy; maintenance therapy; non muscle invasive bladder cancer; prevention of recurrence; transurethral resection

Indexed keywords

BCG VACCINE; EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMATURIA; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; EPIDEMIOLOGIC METHODS; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 79957965313     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09891.x     Document Type: Article

References (36)

1. Lamm DL, Blumenstein BA, Crissman JD, et al,. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9 (Pubitemid 30169376)
2. Lamm DL, van der Meijden APM, Akaza H, et al,. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995; 2 (Suppl. 2): 23-35
3. Kurth KH, Bouffioux C, Sylvester R, et al,. Treatment of superficial bladder tumors: achievement and needs. Eur Urol 2000; 37 (Suppl. 3): 1-9 (Pubitemid 30248573)
4. Akaza H, Koiso K, Ozono S, et al,. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 2003; 33: 382-90 (Pubitemid 43102841)
5. Bohle A, Jocham D, Bock PR,. Intravesical bacillus Calmette-Guérin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-5 (Pubitemid 35461559)
6. Han RF, Pan JG,. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 1216-23 (Pubitemid 43818066)
7. Hinotsu S, Akaza H, Isaka S, et al,. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006; 67: 545-9 (Pubitemid 43343539)
8. Badalament RA, Herr HW, Wong GY, et al,. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette- Guérin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 441-9 (Pubitemid 17045468)
9. Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J,. Control group and maintenance treatment with bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001; 165: 1488-91 (Pubitemid 32410220)
10. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ,. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138: 295-8
11. Herr HW,. Is maintenance Bacillus Calmette-Guérin really necessary? Eur Urol 2008; 54: 971-3
12. Hinotsu S, Akaza H, Ohashi Y, Kotake T,. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86: 1818-26 (Pubitemid 29513052)
13. The Japan Pharmaceutical Manufacturers Association. Japanese Ministerial Ordinance on Standards for Conducting Clinical Trials on Pharmaceuticals. Tokyo: Elsevier Japan K.K. 1997 Ordn. (MHW), No. 28 (in Japanese)
14. Pocock SJ, Simon R,. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975; 31: 103-15
15. Akaza H, Isaka S, Koiso K, et al,. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 1987; 20 (Suppl.): S91-6
16. Hinotsu S, Akaza H, Isaka S, et al,. Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer-the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. Jpn J Cancer Chemother 2002; 29: 73-80 (in Japanese)
17. Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S,. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer: the 6th trial of the Japanese Urological Cancer Research Group (JUCRG)-a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 2004; 45: 600-5 (Pubitemid 38481687)
18. Japan Clinical Oncology Group. National Cancer Institute-Common Toxicity Criteria (NCI-CTC)Version 2.0. Japanese Version of Japan Clinical Oncology Group 2nd Edn. 2001
19. Han B, Enas NH, McEntegart D,. Randomization by minimization for unbalanced treatment allocation. Stat Med 2009; 28: 3329-46
20. Gray RJ,. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 1990; 46: 93-102 (Pubitemid 20245609)
21. Saint F, Irani J, Patard JJ, et al,. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883-8 (Pubitemid 32405306)
22. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R,. Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166: 476-81 (Pubitemid 32652226)
23. Bohle A, Bock PR,. Intravesical bacillus Calmette-Guérin versus Mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63: 682-7
24. Sylvester RJ, van der Meijden APM, Lamm DL,. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
25. Shelley MD, Mason MD, Kynaston H,. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010; 36: 195-205
26. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J,. Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. European Association of Urology (EAU). Eur Urol 2008; 54: 303-14
27. American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer: (Stage Ta, T1, and Tis): 2007 Update. [homepage on the internet]. Available at:. Accessed 11 August 2010
28. Sylvester RJ, van der Meijden A, Witjes JA, et al,. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005; 66: 90-107 (Pubitemid 43049611)
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology TM: Bladder Cancer: Including upper tract tumors and urothelial carcinoma of the prostate v.l.2009. [homepage on the internet]. Available at:. Accessed 31 January 2009
30. The Japanese Urological Association. Bladder Cancer Clinical Practice Guideline. Tokyo: Igaku Tosho Syuppan Co., Ltd., Tokyo, 2009: (in Japanese)
31. Lamm DL, Colombel M, Persad R, et al,. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol 2008; (Suppl. 7): 651-66
32. Malmström PU, Sylvester RJ, Crawford DE, et al,. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56
33. Lamm D, Böhle A, Palou J, et al,. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56. Eur Urol 2010; 57: e7-9; author reply e10-1
34. Gontero P, Bohle A, Malmstrom PU, et al,. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410-29
35. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al,. Club Urolõgico Español de Tratamiento Oncolõgico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 1242-7 (Pubitemid 41318691)
36. Mugiya S, Ozono S, Nagata M, et al,. Long-term outcome of a low-dose intravesical bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005; 35: 395-9 (Pubitemid 41418698)